Impact of immunotherapy on the risk of thromboembolic disease in patients with melanoma

Por: Garay, D, Boluda, N, Moran, L, Benoit-Perejon, J, Colomo, L, de Mena, M, Verduguez, T, Blanco, A, de Soignie, A, Perez, J, Puig, C, Portero, B, Rubio, C, Moreno, J, Garrido, M, Martin, A and Canovas, M

---

Publicada: 1 sep 2021 Ahead of Print: 1 sep 2021

---

---

Filiaciones:
Garay, D:
 Hosp Univ Jaen, Dept Med Oncol, Jaen, Spain

Boluda, N:
 Hosp Univ Morales Meseguer, Dept Med Oncol, Murcia, Spain

Moran, L:
 Hosp Gen Univ Gregorio Maranon, Med Oncol, Fdn Invest Biomed, Madrid, Spain

Benoit-Perejon, J:
 Hosp Univ Jaen, Dept Med Oncol, Jaen, Spain

Colomo, L:
 Inst Catalan Oncol Hosp, Dept Med Oncol, Barcelona, Spain

de Mena, M:
 Hosp Gen Univ Valencia, Med Oncol, Valencia, Spain

:
 Hosp Gen Univ Elche, Med Oncol, Alicante, Spain

Blanco, A:
 Complejo Hosp Toledo, Dept Med Oncol, Toledo, Spain

de Soignie, A:
 Hosp Univ Fuenlabrada, Dept Med Oncol, Madrid, Spain

Perez, J:
 Fdn Jimenez Diaz, Dept Med Oncol, Madrid, Spain

Portero, B:
 Hosp Univ Infanta Leonor, Dept Med Oncol, Madrid, Spain

:
 Hosp Gen Univ Elche, Med Oncol, Alicante, Spain

 Hosp Clin Barcelona, Internal Med, Barcelona, Spain

:
 Hosp Gen Univ Elche, Med Oncol, Alicante, Spain

Garrido, M:
 Hosp Univ Jaen, Dept Med Oncol, Jaen, Spain

Martin, A:
 Hosp Gen Univ Gregorio Maranon, Med Oncol, Fdn Invest Biomed, Madrid, Spain

Canovas, M:
 Hosp Univ Morales Meseguer, Dept Med Oncol, Murcia, Spain